Clinical Trials Logo

Hepatitis C Virus Recurrence clinical trials

View clinical trials related to Hepatitis C Virus Recurrence.

Filter by:
  • None
  • Page 1

NCT ID: NCT01518933 Terminated - Clinical trials for Hepatitis C Virus Recurrence

Effect of LEGALON SIL on Hepatitis C Virus Recurrence in Stable Liver Transplanted Patients

LEG-SIL-LTX-02
Start date: August 2011
Phase: Phase 2
Study type: Interventional

Hepatitis C virus (HCV)-related liver disease is the most common indication for liver transplantation (LT). However, LT does not cure the infection, and therapeutic strategies resulted in very limited efficacy and tolerability in LT recipients. In view of its postulated safety profile, Silibinin seems an ideal drug to be used in the setting of HCV recurrent patients after liver transplantation.